NICE guidance recommends regular review of patients taking GLP-1 agonists, typically every 3-6 months, to assess treatment response, side effects, and ongoing appropriateness of therapy
Studies testing doses from 50 micrograms down to 5 nanograms of BPC-157 per gram of cream vehicle all showed positive effects
Lee, Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 Diabetes: a systematic review and meta-analysis
The native GLP-1 peptide provides the most direct tool for interrogating all of these receptor-mediated pathways at source, without the confounding structural modifications present in GLP-1RA drug compounds
Our goal is to offer solutions for our patients to prevent testicular atrophy, maintain fertility, treat sexual dysfunction and low T, and more